Article
Nitazoxanide reduces atherosclerosis by decreasing polarization of macrophages to proinflammatory M1 phenotype via inhibition of NF-κB pathway.
Biochemical pharmacology - 1 Sept 2026
Czepiel Klaudia, Kuś Katarzyna, Skórkowska Alicja, Wiśniewska Anna, Kuśnierz-Cabala Beata, Kiepura Anna, Jelito Damian, Suski Maciej, Kostogrys Renata B, Franczyk-Żarów Magdalena, Olszanecki Rafał, Jawień Jacek, Stachowicz Aneta
Abstract excerpt
Atherosclerosis and its complications are a leading cause of morbidity and mortality in Western countries. Despite the high prevalence of atherosclerosis, available pharmacological treatments are limited. Nitazoxanide (NTZ) is a broad-spectrum antiparasitic and antiviral drug approved by the Food and Drug Administration (FDA) for the treatment of Giardia- and Cryptosporidium-associated diarrhea in adults and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.